In a combined analysis of 2 trials that randomized patients with CAP (PORT categories III and IV) to ceftaroline or ceftriaxone, those in the ceftaroline group had higher clinical cure rates (84% vs 78%), with the same rates of adverse events. Ceftaroline, recently FDA approved, is an alternative to ceftriaxone which may have better clinical cure rates (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.